Company intelligence / Profile preview

IsoTherapeutics Group

Angleton, Texas, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

IsoTherapeutics Group develops novel diagnostic and therapeutic agents using proprietary technologies with a focus on radiopharmaceuticals. The company provides contract development and manufacturing services from early research to cGMP production. It was acquired by Telix Pharmaceuticals in February 2024 to expand Telix’s U.S. infrastructure for development and manufacturing of radiopharmaceuticals. No specific clinical trial results or marketed drugs are publicly detailed as of June 2025.

Therapeutic areas: OncologyRare DiseasesOther
Modalities: RadiopharmaceuticalSmall moleculeBiologic
Industry: Contract Manufacturing Organization

Partnerships

Telix Pharmaceuticals (acquirer/parent)Various pharmaceutical/life science companies for contract projects

Beyond the preview

Go deeper on IsoTherapeutics Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IsoTherapeutics Group.

Explore the full profile